Clinical Trials Browser

Phase 2 × Capecitabine × Endocrine × Clear all

NCT02595424 2025-12-29

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Phase 2 Active not recruiting

Somatostatinoma, Carcinoma, Neuroendocrine

NCT04339036 2025-12-10

CapTemY90

Phase 2 Recruiting

Neuroendocrine Tumors

NCT07012330 2025-06-10

Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients

Phase 2 Terminated

Neoplasms, Neuroendocrine Tumors

NCT03387592 2025-03-10

SENECA

Phase 2 Terminated

Carcinoma, Neuroendocrine

NCT02736448 2025-01-13

Lu-Ca-S

Phase 2 Terminated

EndocrineGastrointestinalNET

Gastro-entero-pancreatic Neuroendocrine Tumors

NCT03079440 2022-12-06

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Phase 2 Completed

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03279601 2017-09-12

Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor

Phase 2 Unknown

Neuroendocrine Tumors

NCT00398320 2017-03-01

Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors

Phase 2 Completed

40 enrolled 9 charts

Neuroendocrine Tumors

NCT00869050 2016-07-25

Capecitabine and Temozolomide for Neuroendocrine Cancers

Phase 2 Completed

41 enrolled 9 charts

EndocrineGastrointestinalNET

Carcinoid Tumor, Vipoma, Pancreatic Neoplasms, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Gastrinoma, Carcinoma, Medullary, Neuroendocrine Tumors

NCT00602082 2013-08-07

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

Phase 2 Completed

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell